# Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

> **NCT04501367** · PHASE4 · UNKNOWN · sponsor: **Kovach Eye Institute** · enrollment: 60 (estimated)

## Conditions studied

- Vitrectomy
- Macular Pucker
- Retinal Edema

## Interventions

- **DRUG:** Dexamethasone Intracanalicular Insert, 0.4 mg
- **DRUG:** Dexamethasone Intracanalicular Insert, 0.4 mg
- **DRUG:** Prednisone acetate 1%

## Key facts

- **NCT ID:** NCT04501367
- **Lead sponsor:** Kovach Eye Institute
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-27
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501367, "Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04501367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*